Transaction #491 · Form 4 · 0001193125-25-240356
Cabaletta Bio, Inc. · Stock award · Stock Option (Right to Buy)
Cabaletta Bio, Inc. · Transacted October 13, 2025 · Filed October 15, 2025
What does this filing report?
An SEC Form 4 filing for Cabaletta Bio, Inc. records a stock award involving Stock Option (Right to Buy) on October 13, 2025. The reported quantity was 275,000. The filing date is October 15, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Cabaletta Bio, Inc.
- Company CIK
- 0001759138
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 275,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 275,000
- Ownership description
- Not reported
- SEC acceptance time
- Oct 15, 2025, 4:39 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Gavel Steve ↗
CHIEF COMMERCIAL OFFICER
CIK 0002090785
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 275,000
- Conversion / exercise price
- 2.49
- Exercise date
- Not reported
- Expiration date
- October 12, 2035
Filing footnotes & remarks
- F1
- The stock option has been granted pursuant to the Cabaletta Bio, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4).
- F2
- 25% of the shares underlying this option shall vest and become exercisable on October 13, 2026, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.